Matthew Keller
Stock Analyst at HC Wainwright & Co.
(n/a)
# 5,015
Out of 5,182 analysts
12
Total ratings
n/a
Success rate
-31.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.25 | +1,020.00% | 2 | Feb 10, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $6 → $24 | $1.74 | +1,279.31% | 2 | Jan 27, 2026 | |
| IFRX InflaRx | Reiterates: Buy | $6 | $1.03 | +482.52% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $2.43 | +352.67% | 2 | Dec 17, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $30.53 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $2.69 | +1,052.42% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.24 | +148.62% | 1 | Aug 26, 2025 |
Phio Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $14
Current: $1.25
Upside: +1,020.00%
60 Degrees Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $6 → $24
Current: $1.74
Upside: +1,279.31%
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $1.03
Upside: +482.52%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $2.43
Upside: +352.67%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $30.53
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $2.69
Upside: +1,052.42%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.24
Upside: +148.62%